Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
A phase 3 trial of Durvalumab, Tremelimumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin is a phase 3 interventional study registered as NCT04960709 by AstraZeneca, with 712 participants enrolled, started 2021-08-05 and due to reach its primary completion in 2026-03-02. Interventions recorded: Durvalumab, Tremelimumab, Enfortumab Vedotin and Radical Cystectomy.
Similar pages
not linked directly; found by shared links- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Tremelimumab, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Tremelimumab, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialDurvalumab and Tremelimumab for Pediatric Malignancies
Shares Tremelimumab, Durvalumab, AstraZeneca and the tag pipeline.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialAn Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Shares Enfortumab vedotin, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Tremelimumab, Durvalumab, AstraZeneca and the tag pipeline.
- TrialBCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Tremelimumab, Durvalumab, AstraZeneca and the tag pipeline.